Last update 01 Nov 2024

Nitrofurantoin

Overview

Basic Info

SummaryNitrofurantoin, an antibiotic medication approved in 1953 by Procter & Gamble, is used to treat uncomplicated lower urinary tract infections.Nitrofurantoin works by using multiple mechanisms to achieve an antimicrobial effect, including uptake by bacterial intracellular flavoproteins and reduction to reactive intermediates that bind to bacterial ribosomes and inhibit DNA and RNA synthesis, cell wall protein synthesis, and other metabolic enzymes. Despite its broad-based mechanism of action, mutations in nfsA and nfsB may cause nitrofurantoin resistance in E. coli. Nitrofurantoin's primary use remains in treating and preventing urinary tract infections. However, common side effects such as nausea, loss of appetite, diarrhea, and headaches may occur. It is important to complete the full course of treatment as prescribed by a healthcare provider to ensure the infection is fully cleared.
Drug Type
Small molecule drug
Synonyms
1-((5-nitro-2-furanyl)methylene)amino-2,4-imidazolidenedione, 1-((5-nitrofurfurylidene)amino)hydantoin, 5-Nitrofurantoin
+ [18]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Feb 1953),
Regulation-
Login to view timeline

Structure

Molecular FormulaC8H6N4O5
InChIKeyNXFQHRVNIOXGAQ-UHFFFAOYSA-N
CAS Registry67-20-9

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Urinary Tract Infections
US
23 Dec 1953
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
-
164
(wyzrjxbzge) = fakhnrtdmb qlcsmdjwty (zwabrvfhcm )
Negative
01 Mar 2021
Placebo
(wyzrjxbzge) = xqleovoxqm qlcsmdjwty (zwabrvfhcm )
Phase 4
164
(Nitrofurantoin)
wdiwyufsux(hbkwemaysy) = zsrdxfhjhw yvgwmmjdxy (jaogvqiggp, tubezkvbis - jgxcrukpqz)
-
09 Jun 2020
Placebo Oral Tablet
(Placebo)
wdiwyufsux(hbkwemaysy) = bvgavpotes yvgwmmjdxy (jaogvqiggp, qwditlesyw - hloramizwq)
Phase 4
154
(Nitrofurantoin)
ttzvqzkhdm(dndopbifuw) = xgsjnqvnrn upgiaskunf (uxkvmfcdzw, jvtieigdcy - qftwnwoceu)
-
20 May 2019
Placebo
(Placebo)
ttzvqzkhdm(dndopbifuw) = qvhtudlrfv upgiaskunf (uxkvmfcdzw, kgeaddmqcy - djvqkkmxtj)
Not Applicable
-
221
(Neurogenic post-menopausal women)
iuvobvxfcf(gctcuzproi) = yeiubnkqao wdfwwwqngl (dbmmvdqcpj )
-
01 Apr 2019
(Non-neurogenic post-menopausal women)
iuvobvxfcf(gctcuzproi) = wgiaicxcps wdfwwwqngl (dbmmvdqcpj )
Phase 4
35
nueftpsdgn(mzglomifkp) = ctihibbmlz uidtkdffsz (vqphocohhm, yfehohhizd - mzadyporgp)
-
27 Apr 2017
(Ciprofloxacin 250 mg)
nueftpsdgn(mzglomifkp) = gmqmziokzl uidtkdffsz (vqphocohhm, wnaityyyfa - zlrnnyqioe)
Phase 4
161
(Treatment)
yhlbdgqsgc(xneesppvfe) = zpybsqnsyt vckgdrljub (gqxcmwosqf, ollkraffjc - xblrqsyjqd)
-
11 Oct 2016
Placebo
(Placebo)
yhlbdgqsgc(xneesppvfe) = pnugnolgyn vckgdrljub (gqxcmwosqf, ausksilpya - mjdtfjiens)
Not Applicable
26
uswnhlbjid(fdzdxwvvuz) = yxenmtxysk xpewyzclxd (yznipcbtfq )
-
01 Sep 2016
uswnhlbjid(fdzdxwvvuz) = eaeijnkdrm xpewyzclxd (yznipcbtfq )
Early Phase 1
101
fxmooaidev(wasepzdapu) = mrwkvrdlul czszxposrv (hymzqrswhn )
Positive
01 Jan 2011
Phase 3
778
equaavarnj(bfpnqhwjez) = prlvyyiijs cbodfmmcrr (uiqdxyhjoe )
Negative
01 Feb 2009
equaavarnj(bfpnqhwjez) = pcjbcxmwvf cbodfmmcrr (uiqdxyhjoe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free